PCOS explained · Metabolic health · Hormone signaling
Your ovaries listen to insulin, too. Here is why that connection matters—and where inositol fits into the research.
Most of us meet insulin in a conversation about blood sugar. But it also helps influence the hormones made by the ovaries. That makes insulin part of the reproductive-health conversation, especially in polycystic ovary syndrome (PCOS).1
The surprising connection: higher insulin levels can encourage ovarian androgen production. Blood-sugar regulation and reproductive hormones are linked through the same messenger.1
How insulin reaches the hormone conversation
Androgens, including testosterone, are normal hormones in women. In PCOS, excess androgen activity can be one part of the condition. Insulin can stimulate the ovarian cells that make androgens. It can also reduce the liver’s production of sex hormone-binding globulin (SHBG), a protein that binds sex hormones in the blood. Less SHBG can mean more biologically available androgens.1
This is a biological explanation, not a way to diagnose yourself from a symptom or a promise that changing one laboratory number will resolve PCOS. The condition involves multiple interacting pathways.1
Can blood sugar be normal while insulin is higher?
Yes. When tissues respond less effectively to insulin, the pancreas may compensate by releasing more. That extra insulin can help keep glucose within the normal range for a time. A normal glucose result therefore does not, by itself, tell the whole story about insulin sensitivity.2
This does not mean everyone needs a fasting-insulin test. The international guideline recommends assessing glucose status at PCOS diagnosis and repeating assessment every one to three years according to individual risk. A 75-g oral glucose tolerance test is the most accurate option in PCOS; routine insulin assays have limited clinical usefulness.3
Why researchers study inositol
Inositols participate in the pathways cells use to relay hormone signals. A 2024 systematic review evaluated 30 randomized trials involving 2,230 participants with PCOS. It found possible benefits for some metabolic measurements, but overall evidence remained limited and inconclusive.4
| One research example | What it means |
|---|---|
| In the two trials contributing to this HOMA-IR estimate, participants with PCOS took 2 g myo-inositol plus folic acid daily for 12 weeks, compared with folic acid alone. | For HOMA-IR, an estimate of insulin resistance, two trials (70 participants) favored inositol: mean difference −1.24; 95% confidence interval −1.50 to −0.99. |
| The certainty for that result was very low, because of bias and small samples. | A better laboratory estimate does not establish improved symptoms, fertility, or benefit from WrenLife’s finished formula. |
NHMRC-funded; one author disclosed unrelated nutraceutical funding and complementary-medicine speaking fees. See the paper’s full disclosures.4
The guideline allows consideration of inositol according to personal preferences, while emphasizing limited clinical benefits. It does not endorse a particular type, dose, or combination. A 40:1 ratio should therefore not be presented as a proven best ratio.3
For a fuller comparison of study findings, read our inositol and PCOS evidence review.
A useful question for your next appointment
“How are we checking my metabolic health alongside my cycle and hormone symptoms?” Bring your current medicines and supplements to that conversation. A useful plan starts with your goals and the outcomes you want to track.
WrenLife sells the product featured here. This article is educational and is not an individual treatment plan. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Scientific references
- Dumesic DA et al. (2015). Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocrine Reviews 36(5):487–525.
- Wilcox G. (2005). Insulin and Insulin Resistance. Clinical Biochemist Reviews 26(2):19–39.
- Teede HJ et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. JCEM 108(10):2447–2469. See recommendations 1.9 and 4.7.
- Fitz V et al. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. JCEM 109(6):1630–1655.
